News Image

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Provided By GlobeNewswire

Last update: Aug 30, 2024

- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications
- No new safety signals observed at interim analysis
- Primary endpoint of progression free survival projected to be reached in the first half of 2025

Read more at globenewswire.com

IO BIOTECH INC

NASDAQ:IOBT (6/12/2025, 4:30:02 PM)

1.5

0 (0%)



Find more stocks in the Stock Screener

Follow ChartMill for more